Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Ato gepant is a novel, orally bioavailable small molecule belonging to the class of calcitonin gene-related peptide (CGRP) receptor antagonists, also known as gepants. Developed by AbbVie and approved by regulatory bodies including the US FDA, it represents a significant advancement in the treatment of migraine disorders. The molecular formula of Ato gepant is C27H31ClF3N5O4, with a CAS number of 2180693-24-3. This compound functions by selectively blocking the CGRP receptor, thereby inhibiting the vasodilation and neurogenic inflammation pathways that are central to migraine pathophysiology. Unlike traditional triptans, which act on serotonin receptors and can cause vasoconstriction, Ato gepant offers a distinct mechanism of action that avoids cardiovascular risks associated with vasoconstrictive agents.
Clinically, Ato gepant is indicated for both the acute treatment of migraine attacks with or without aura in adults and for the preventive treatment of episodic migraine in adults. Its efficacy has been demonstrated in multiple phase three clinical trials, showing rapid pain relief and freedom from the most bothersome symptom within two hours of administration. Furthermore, its role in prevention involves daily dosing to reduce the frequency of migraine days over a month. A key advantage of this medication is its favorable safety profile, particularly for patients who cannot tolerate triptans due to comorbidities such as hypertension or ischemic heart disease. Common side effects include nausea, dry mouth, and fatigue, though these are generally mild and transient. As a non-vasoconstrictive option, Ato gepant expands therapeutic choices for a broad patient population, addressing an unmet need in migraine management. Ongoing research continues to explore its potential in other neurological conditions involving CGRP signaling, solidifying its position as a cornerstone therapy in modern neurology.